Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus Load

Paloma Gil(Hospital Universitario Fundación Jiménez Díaz), Manuel Fernández Guerrero(Hospital Universitario Fundación Jiménez Díaz), Carmen Yera(Hospital Universitario Fundación Jiménez Díaz), Rosa García(Universidad Autónoma de Madrid), Alberto Arranz(Hospital Universitario Príncipe de Asturias), Juan José Granizo(Universidad Autónoma de Madrid), Vicente Estrada(Instituto de Salud Carlos III), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Pablo Rivas(Hospital Universitario Fundación Jiménez Díaz)
Clinical Infectious Diseases
September 21, 2004
10.1086/423385
Cited by 28

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343
Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals
|Mucosal Immunology|2014|332